Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
01 12 2019
Historique:
pubmed: 24 9 2019
medline: 23 6 2020
entrez: 24 9 2019
Statut: ppublish

Résumé

Stratum 1 of ACNS1123 (ClinicalTrials.gov identifier: NCT01602666), a Children's Oncology Group phase II trial, evaluated efficacy of reduced-dose and volume of radiotherapy (RT) in children and adolescents with localized nongerminomatous germ cell tumors (NGGCTs). The primary objective was to evaluate the impact of reduced RT on progression-free survival (PFS) with a goal of preserving neurocognitive function. Patients received six cycles of chemotherapy with carboplatin and etoposide alternating with ifosfamide and etoposide, as used in the Children's Oncology Group predecessor study (ACNS0122; ClinicalTrials.gov identifier: NCT00047320). Patients who achieved a complete response (CR) or partial response (PR) with or without second-look surgery were eligible for reduced RT, defined as 30.6 Gy whole ventricular field and 54 Gy tumor-bed boost, compared with 36 Gy craniospinal irradiation plus 54 Gy tumor-bed boost used in ACNS0122. A total of 107 eligible patients were enrolled. Median age was 10.98 years (range, 3.68 to 21.63) and 75% were male. Sixty-six of 107 (61.7%) achieved a CR or PR and proceeded to reduced RT. The 3-year PFS and overall survival and standard error values were 87.8% ± 4.04% and 92.4% ± 3.3% compared with 92% and 94.1%, respectively, in ACNS0122. There were 10 recurrences, prompting early study closure; however, after a retrospective central review, only disease in eight of 66 (12.1%) patients eligible for reduced RT subsequently progressed; six patients had distant spinal relapse alone and two had disease with combined local plus distant relapse. Serum and CSF α-fetoprotein and β-human chorionic gonadotropin levels were not associated with PFS. Patients with localized NGGCT who achieved a CR or PR to chemotherapy and received reduced RT had encouraging PFS similar to patients in ACNS0122 who received full-dose craniospinal irradiation. However, the patterns of failure were distinct, with all patients having treatment failure in the spine.

Identifiants

pubmed: 31545689
doi: 10.1200/JCO.19.00701
pmc: PMC6900864
doi:

Banques de données

ClinicalTrials.gov
['NCT01602666', 'NCT00047320']

Types de publication

Clinical Trial, Phase II Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

3283-3290

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States

Références

Neuropediatrics. 1992 Oct;23(5):228-34
pubmed: 1454140
Neuro Oncol. 2012 Sep;14(9):1194-200
pubmed: 22869621
BMC Genomics. 2010 Feb 24;11:132
pubmed: 20178649
Neurology. 2007 May 15;68(20):1668-73
pubmed: 17502547
Oncologist. 2008 Jun;13(6):690-9
pubmed: 18586924
Neuro Oncol. 2001 Jul;3(3):174-83
pubmed: 11465398
Neuro Oncol. 2017 Nov 29;19(12):1661-1672
pubmed: 29048505
J Child Neurol. 2009 Nov;24(11):1439-45
pubmed: 19841431
Neuropediatrics. 1994 Feb;25(1):26-32
pubmed: 8208347
Pediatr Blood Cancer. 2004 Aug;43(2):126-33
pubmed: 15236278
J Clin Oncol. 1996 Nov;14(11):2908-15
pubmed: 8918487
J Clin Oncol. 2015 Aug 1;33(22):2464-71
pubmed: 26101244
Pediatr Blood Cancer. 2010 Mar;54(3):377-83
pubmed: 20063410
J Okla State Med Assoc. 2015 Apr;108(4):129-35
pubmed: 26263577
Pediatr Blood Cancer. 2012 Sep;59(3):536-9
pubmed: 22555997
Curr Neurol Neurosci Rep. 2004 May;4(3):253-62
pubmed: 15102352
Lancet Oncol. 2015 Sep;16(9):e470-e477
pubmed: 26370356

Auteurs

Jason Fangusaro (J)

Children's Healthcare of Atlanta, Atlanta, GA.
Emory University School of Medicine, Atlanta, GA.

Shengjie Wu (S)

St Jude Children's Research Hospital, Memphis, TN.

Shannon MacDonald (S)

Massachusetts General Hospital Cancer Center, Boston, MA.

Erin Murphy (E)

Cleveland Clinic, Cleveland, OH.

Dennis Shaw (D)

Children's Hospital and Regional Medical Center, Seattle, WA.

Ute Bartels (U)

Hospital for Sick Children, Toronto, Ontario, Canada.

Soumen Khatua (S)

MD Anderson Cancer Center, Houston, TX.

Mark Souweidane (M)

Weill Cornell Medicine and Memorial Sloan-Kettering Cancer Center, New York, NY.

Hsiao-Ming Lu (HM)

Massachusetts General Hospital Cancer Center, Boston, MA.

David Morris (D)

University of North Carolina at Chapel Hill, Chapel Hill, NC.

Ashok Panigrahy (A)

Children's Hospital of Pittsburgh, Pittsburgh, PA.

Arzu Onar-Thomas (A)

St Jude Children's Research Hospital, Memphis, TN.

Maryam Fouladi (M)

Cincinnati Children's Hospital, Cincinnati, OH.

Amar Gajjar (A)

St Jude Children's Research Hospital, Memphis, TN.

Girish Dhall (G)

Children's Hospital Los Angeles, Los Angeles, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH